MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis

[1]  Kiyoko Kato,et al.  Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer , 2013, Oncology reports.

[2]  H. Romanowicz,et al.  Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women. , 2012, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[3]  P. Lønning,et al.  SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. , 2012, European journal of cancer.

[4]  R. Leng,et al.  UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation , 2011, Cell cycle.

[5]  B. Kong,et al.  MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis , 2011, Human Cell.

[6]  C. Prives,et al.  The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.

[7]  S. Noda,et al.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer , 2009, Human Cell.

[8]  S. Noda,et al.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer , 2009, Human Cell.

[9]  R. Scott,et al.  Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. , 2009, Gynecologic oncology.

[10]  D. Vergara,et al.  Hormonal carcinogenesis and socio‐biological development factors in endometrial cancer: A clinical review , 2008, Acta obstetricia et gynecologica Scandinavica.

[11]  E. Taioli,et al.  Endometrial hyperplasia, endometrial cancer and prevention: gaps in existing research of modifiable risk factors. , 2008, European journal of cancer.

[12]  K. Lu,et al.  Genetic polymorphisms and endometrial cancer risk , 2008, Expert review of anticancer therapy.

[13]  J. Buring,et al.  MDM2 SNP309 Is Associated with Endometrial Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  G. Lane Obesity and gynaecological cancer , 2008, Menopause international.

[15]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[16]  Carl W. Miller,et al.  Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. , 2007, Gynecologic oncology.

[17]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[18]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[19]  Thomas A Trikalinos,et al.  Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. , 2006, American journal of epidemiology.

[20]  J. W. Kim,et al.  Single nucleotide polymorphism: a new risk factor for endometrial cancer? , 2005, Future oncology.

[21]  Patrick Neven,et al.  Endometrial cancer , 2005, The Lancet.

[22]  Ammarin Thakkinstian,et al.  Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. , 2005, American journal of epidemiology.

[23]  J. Ioannidis,et al.  Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power , 2005, European Journal of Human Genetics.

[24]  Y. Haupt,et al.  Mdm2 in growth signaling and cancer , 2005, Growth factors.

[25]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[26]  Ian Purvis,et al.  Detection of genotyping errors by Hardy–Weinberg equilibrium testing , 2004, European Journal of Human Genetics.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  H. Kinyamu,et al.  Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.

[29]  S. Safe,et al.  Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. , 2003, Endocrinology.

[30]  J. Blaydes,et al.  p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. , 2003, Cancer research.

[31]  Aravinda Chakravarti,et al.  Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. , 2003, American journal of human genetics.

[32]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[33]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[34]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[35]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[36]  P. Lønning,et al.  MDM2 SNP309 and risk of endometrial cancer. , 2013, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[37]  A. Nardulli,et al.  Cell- and ligand-specific regulation of promoters containing activator protein-1 and Sp1 sites by estrogen receptors alpha and beta. , 2005, The Journal of biological chemistry.

[38]  S. Safe Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. , 2001, Vitamins and hormones.